Signal Explorer

Regulatory Designation Only Lead Asset Progress

Net Loss Reported Capital Raising Uncertainty Disclosed Ipo Net Proceeds Disclosure Competition Disclosure Financing Activities Cash Flow Disclosure Nyse Listing Disclosure Material Weakness In Internal Controls Disclosed Cash Flow Statement Investing Activities Power Of Attorney Disclosure Stock Price As Of Filing Date Hipaa Fraud Abuse Laws Disclosure Cybersecurity Breach Reputational Harm Disclosure Nol Carryforward Expiration Disclosure

Net Loss Reported Fast Track Designation Received Patient Retention High Fast Track Granted Orphan Status Granted Interim Data Positive Expanded Access Program Active Gene Therapy Aav Enrollment Ahead Of Schedule

Regulatory Designation Only Lead Asset Progress Clinical Trial Result Clinical Hold Indication Expansion

Orphan Drug Designation

Classified Board Director Election Director Continuity Stated Rsu Psu Vesting Schedule Disclosed

Management Exodus

Codm Segment Reporting Disclosure Cash Flow Statement Investing Activities Net Loss Reported Financing Activities Cash Flow Disclosure Operating Lease Rent Expense Disclosed Material Weakness In Internal Controls Disclosed Fast Track Designation Received Interim Data Positive Liquidity Position Snapshot Disclosed Patient Retention High Other Income Expense Disclosure Fast Track Granted

Regulatory Designation Only Clinical Trial Result Clinical Hold

Net Loss Reported Interim Data Positive Patient Retention High Enrollment Ahead Of Schedule Protocol Amended Kol Endorsement Publication Positive Fda Aligned Expanded Access Program Active

Clinical Trial Result Lead Asset Progress Combination Therapy Mentioned Clinical Hold Indication Expansion Patient Enrollment Velocity